IL5 and asthma: These targeted immunotherapy, in particular anti-IgE and anti-IL5 antibodies, have been shown to reduce asthma severity and frequency of acute exacerbation and achieve steroid-sparing effect in patients with Th2-skewed asthma endotype [11,12,13,14].